The Journal of Experimental Medicine
ELISpot, FluoroSpot and ELISA kits from Mabtech
  Home | Help | Feedback | Subscriptions | Archive | Search | Table of Contents

Published online 6 November 2000.
This Article
Right arrow Full Text
Right arrow Full Text (PDF, 221K)
Right arrow Alert me when this article is cited
Right arrow Citation Map
Services
Right arrow Email this article
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new content in the JEM
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Nakayama, M.
Right arrow Articles by Yagita, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Nakayama, M.
Right arrow Articles by Yagita, H.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
© The Rockefeller University Press, 0022-1007/2000/11/1373/ $5.00
The Journal of Experimental Medicine, Volume 192, Number 9, November 6, 2000 1373-1380


Brief Definitive Reports

Involvement of TWEAK in Interferon {gamma}–stimulated Monocyte Cytotoxicity

Masafumi Nakayamaa,b, Nobuhiko Kayagakia,c, Noriko Yamaguchia,c, Ko Okumuraa,c, and Hideo Yagitaa,c
a Department of Immunology, Juntendo University School of Medicine, Tokyo 113-8421, Japan
b Allergy Research Center, Juntendo University School of Medicine, Tokyo 113-8421, Japan
c Core Research for Evolutional Science and Technology of Japan Science and Technology Corporation, Tokyo 101-0062, Japan

Correspondence to: Hideo Yagita, Dept. of Immunology, Juntendo University School of Medicine, 2-1-1 Hongo, Bunkyo-ku, Tokyo 113-8421, Japan. Tel:81-3-3818-9284 Fax:81-3-3813-0421

TWEAK, a new member of the tumor necrosis factor (TNF) family, induces cell death in some tumor cell lines, but its physiological functions are largely unknown. In this study, we investigated the expression and function of TWEAK in human peripheral blood mononuclear cells (PBMCs) by using newly generated anti–human TWEAK mAbs. Although freshly isolated PBMCs expressed no detectable level of TWEAK on their surfaces, a remarkable TWEAK expression was rapidly observed on monocytes upon stimulation with interferon (IFN)-{gamma} but not with IFN-{alpha} or lipopolysaccharide. Cytotoxic activity of IFN-{gamma}–stimulated monocytes against human squamous carcinoma cell line HSC3 was inhibited partially by anti-TWEAK mAb alone and almost completely by combination with anti-TRAIL (TNF-related apoptosis-inducing ligand) mAb. These results revealed a novel pathway of monocyte cytotoxicity against tumor cells that is mediated by TWEAK and potentiated by IFN-{gamma}.

Key Words: TWEAK, TRAIL, IFN-{gamma}, monocyte, cytotoxicity


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:



  Home | Help | Feedback | Subscriptions | Archive | Search
TABLE OF CONTENTS